Groningen-based Griphingo Pharmaceuticals conducts applied research into the development of an innovative inhalation therapy for COPD patients. For the development of this therapy, the start-up works with a network of COPD and medicine development experts from the Northern region.
Current COPD treatment is not effective enough to suppress the inflammatory reactions in the lungs of COPD patients and also has many side effects. Griphingo hopes to curb these inflammatory reactions with a new molecule, which has an alternative target compared to existing medication, in order to significantly improve the quality of life of COPD patients. In the coming period, Griphingo will focus on optimising the molecules in collaboration with Symeres and testing efficacy in collaboration with Aquilo.
These cookies make sure the website functions properly. These cookies also provide us to anonymously monitor website statistics. Because these cookies are essential for the website, you can not disable them without compromising the functionality of the website.
These cookies collect data that we use to understand how our website is used and perceived. These cookies also help us to optimize the website for the best user experience.
These cookies allow ad-networks to monitor your online behaviour so they can display relevant ads based on your interest and online behaviour. These cookies also prevent the same ads from being displayed over and over.
